Skip to main content
. 2015 Nov 16;5:15911. doi: 10.1038/srep15911

Figure 5. TM pretreatment potentiates cisplatin-mediated p38 activation and EGFR serine phosphorylation.

Figure 5

(A) ECC-1 cells were treated with or without TM (30 μM) for 48 h, after which the cells were exposed to cisplatin (30 μM) for the indicated times. The levels of p-p38 or p38 were measured by Western blot analysis. (B) ECC-1 cells were treated with or without TM (30 μM) for 48 h, after which the cells were exposed to vehicle or cisplatin (30 μM) for the indicated times. EGFR phosphorylation was determined by Western blot analysis using site specific antibodies for Tyr-1068 or Ser-1046/7. (C) ECC-1 cells were treated with vehicle, EGF (20 ng/ml, 3 h) or cisplatin (120 μM, 6 h) with or without TM pretreatment (30 μM, 48 h). The levels of EGFR or GAPDH were measured by Western blot analysis.